Measuring performance status in pediatric patients with brain tumors - Experience of the HIT-GBM-C protocol

Pediatric Blood and Cancer

Volumn 55, Issue 3, 2010, Pages 520-524

  Wolff, Johannes E A ^a   Mohiuddin, Kamran ^a   Jorch, Norbert ^b   Graf, Norbert ^c   Wagner, Sabine ^d   Vats, Tribahwan ^a   Gnekow, Astrid ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Gilead Children's Hospital   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e Children's Hospital   (Germany)

Author keywords

Brain stem glioma; CNS tumors; Psychosocial; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; BRAIN TUMOR; CANCER GRADING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL DECISION MAKING; DISABILITY; DISEASE SEVERITY; FEMALE; FERTIGKEITENSKALA MUNSTER HEIDELBERG SCALE; GLIOMA; HEALTH STATUS; HUMAN; INTENSIVE CARE UNIT; MALE; MEASUREMENT; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RATING SCALE; SCORING SYSTEM; SURVIVAL; BRAIN STEM TUMOR; CLINICAL TRIAL; DAILY LIFE ACTIVITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; QUALITY OF LIFE; QUESTIONNAIRE;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; BRAIN NEOPLASMS; BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOMA; HEALTH STATUS; HUMANS; MALE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 77955488183     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22566     Document Type: Article

References (28)

1. Wolff JE, Classen CF,Wagner S, et al. Subpopulations of malignant gliomas in pediatric patients: Analysis of the HIT-GBM database. J Neurooncol 2008;87:155-164.
2. Wagner S,Warmuth-Metz M, Emser A, et al. Treatment options in childhood pontine gliomas. J Neurooncol 2006;79:281-287.
3. Eiser C. Children's quality of life measures. Arch Dis Child 1997;77:350-354.
4. Eiser C, Cool P, Grimer R, et al. The role of monitoring in determining quality of life following treatment for a bone tumor. Int J Behav Med 1997;4:397-414. (Pubitemid 127530702)
5. Wolff JE, Westphal S, Molenkamp G, et al. Treatment of pediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer 2002;87:945-949.
6. Wolff JE, Wagner S, Reinert C, et al. Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol 2006;79:315-321. (Pubitemid 44363736)
7. Wolff JE, Molenkamp G, Westphal S, et al. Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer 2000;89:2131-2137.
8. Wolff JE, Kramm C, Kortmann RD, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 2008;90:309-314.
9. Wolff JE, Daumling E, Dirksen A, et al. Munster Heidelberg Abilities Scale - A measuring instrument for global comparison of illness sequelae. Klin Padiatr 1996;208:294-298.
10. Kosch A, Molenkamp G, Daumling E, et al. Assessment of independence in daily life in pediatric oncology by FMH-questionnaire. Klin Padiatr 1998;210:390-394.
11. Wolff JE, Huttermann U, Askins MA. Quantifying health status outcomes in pediatric medulloblastoma patients. Anticancer Res 2007;27:523-529.
12. Muller HL, Gebhardt U, Etavard-Gorris N, et al. Prognosis and sequela in patients with childhood craniopharyngioma - Results of HIT-ENDO and update on KRANIOPHARYNGEOM 2000. Klin Padiatr 2004;216:343-348.
13. Muller HL, Gebhardt U, Faldum A, et al. Functional capacity and body mass index in patients with sellar masses-cross-sectional study on 403 patients diagnosed during childhood and adolescence. Childs Nerv Syst 2005;21:539-545.
14. Muller HL. Childhood craniopharyngioma. Recent advances in diagnosis, treatment and follow-up. Horm Res 2008;69:193-202.
15. Mulhern RK, Reddick WE, Palmer SL, et al. Neurocognitive deficits in medulloblastoma survivors and white matter loss. Ann Neurol 1999;46:834-841.
16. Le Gales C, Costet N, Gentet JC, et al. Cross-cultural adaptation of a health status classification system in children with cancer. First results of the French adaptation of the Health Utilities Index Marks 2 and 3. Int J Cancer Suppl 1999;12:112-118.
17. Kennedy CR, Leyland K. Comparison of screening instruments for disability and emotional/behavioral disorders with a generic measure of health-related quality of life in survivors of childhood brain tumors. Int J Cancer Suppl 1999;12:106-111.
18. Szecket N, Medin G, Furlong WJ, et al. Preliminary translation and cultural adaptation of Health Utilities Index questionnaires for application in Argentina. Int J Cancer Suppl 1999;12:119-124.
19. Landgraf JM. Measuring health-related quality of life in pediatric oncology patients: A brief commentary on the state of the art of measurement and application (discussion). Int J Cancer Suppl 1999;12:147-150.
20. Kramer JA, Curran D, Piccart M, et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 2000;36:1498-1506.
21. Efficace F, Bottomley A, Smit EF, et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients?Amultivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 2006;17:1698-1704.
22. Blazeby JM, Vickery CW. Quality of life in patients with cancers of the upper gastrointestinal tract. Exp Rev Anticancer Ther 2001;1:269-276.
23. Efficace F, Therasse P, Piccart MJ, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An International Multicenter Study. J Clin Oncol 2004;22:3381-3388.
24. de GraeffA, de Leeuw JR, Ros WJ, et al. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 2001;37:332-339.
25. Klein M, Postma TJ, Taphoorn MJ, et al. The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology 2003;61:1796-1798.
26. Sehlen S, Lenk M, Hollenhorst H, et al. Quality of life (QoL) as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy. Onkologie 2003;26:38-43.
27. Meyers CA, Hess KR, Yung WK, et al. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 2000;18:646-650.
28. Bampoe J, Ritvo P, Bernstein M. Quality of life in patients with brain tumor: What's relevant in our quest for therapeutic efficacy. Neurosurg Focus 1998;4:e6.